Endo Says FTC Is Overreacting To Latest Impax Opioid Deal

By Isaac Monterose · April 27, 2021, 9:43 PM EDT

Endo Pharmaceuticals is pushing for the dismissal of a Federal Trade Commission antitrust suit alleging it entered a second "pay-for-delay" agreement with Impax Laboratories over Endo's Opana ER painkiller, arguing the...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

FEDERAL TRADE COMMISSION v. ENDO PHARMACEUTICALS INC. et al

Case Number

1:21-cv-00217

Court

District Of Columbia

Nature of Suit

Anti-Trust

Date Filed

January 25, 2021